Human papillomavirus–related conditions in women with multiple sclerosis receiving disease-modifying therapies: A Pharmacovigilance disproportionality analysis from the WHO vigibase®
This study identified a potential signal of disproportionate reporting of HPV-related conditions with fingolimod, ocrelizumab and natalizumab based on real-world pharmacovigilance data. These exploratory findings highlight the need for population-based pharmacoepidemiological studies to confirm the signal, while HPV vaccination and cancer screening remain key preventive measures for patients on MS-DMTs.
Authors
- Constance Bordet (ORCID: https://orcid.org/0009-0007-7422-6976)
- Pauline Laigo (ORCID: https://orcid.org/0009-0003-1312-4811)
- Anne-Caroline Papeix
- Laure Thomas (ORCID: https://orcid.org/0000-0003-4777-5690)
- Lamiae Grimaldi
- Oumaïma Maachi
Institutions
- Université Paris Cité (FR)
- Université Paris-Saclay (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Fondation Ophtalmologique Adolphe de Rothschild (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Bicêtre Hospital (FR)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1177/13524585251377411
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00